Pancreatic Cancer Treatment Guidelines

First-Line Chemotherapy Options

• The American Society of Clinical Oncology recommends FOLFIRINOX or gemcitabine plus nab-paclitaxel as the preferred regimens for patients with good performance status (ECOG 0-1), extending median survival to approximately 8-12 months compared to 5.8-7 months without treatment 1, 2.
• The National Comprehensive Cancer Network recommends gemcitabine monotherapy for patients with moderate performance status, extending median survival to approximately 6.6 months 1, 2, 3.
• Performance status is the single most important prognostic factor and should guide treatment decisions, according to the European Society for Medical Oncology 1.

Second-Line Treatment Options

• The American Society of Clinical Oncology recommends the OFF regimen (5-FU/Leucovorin plus Oxaliplatin) after gemcitabine failure 2, 3.
• The National Comprehensive Cancer Network recommends nanoliposomal irinotecan with 5-FU/Leucovorin as an alternative second-line option 3.

Palliative Care

• The European Society for Medical Oncology recommends opioids (morphine) as the drugs of choice for pain control, preferably administered orally 2, 3, 4, 5.
• The American Society of Clinical Oncology recommends celiac plexus blockade (percutaneous or EUS-guided) for patients with poor opioid tolerance, with analgesic response rates of 50-90% 2, 4, 5.
• The National Comprehensive Cancer Network recommends hypofractionated radiotherapy to improve pain control and reduce analgesic consumption 2, 3, 4.
• The European Society for Medical Oncology recommends endoscopic metal stent placement for biliary obstruction, particularly for patients with life expectancy >3 months 2, 3.
• The American Society of Clinical Oncology recommends expandable metal stent placement for duodenal obstruction 2, 3.
• The National Comprehensive Cancer Network recommends metoclopramide to help with gastric emptying 3, 4.
• The European Society for Medical Oncology recommends pancrelipase replacement with meals for patients with exocrine pancreatic insufficiency 5.
• The American Society of Clinical Oncology recommends consultation with a nutritionist for dietary assessment 5.

Common Pitfalls to Avoid

• The European Society for Medical Oncology advises against pursuing unproven therapies at the expense of evidence-based treatments that have demonstrated survival benefits in randomized controlled trials 4.
• The American Society of Clinical Oncology advises against delaying chemotherapy initiation in patients with good performance status—FOLFIRINOX and gemcitabine/nab-paclitaxel significantly improve both survival and quality of life 2.
• The National Comprehensive Cancer Network advises against undertreating pain—aggressive pain management with opioids and interventional procedures is essential for quality of life 4, 5.
• The European Society for Medical Oncology advises against overlooking early palliative care consultation—this improves symptom management and psychosocial support throughout the disease trajectory 5.